Author:
Wadhwa Meenu,Kang Hye-Na,Hamel Hugo,Jivapaisarnpong Teeranart,Allam Mai,Alway Beverley,Aprea Patricia,Blades Carolina,Chirachanakul Parichard,Chong Sannie,Dahlan Juliati,Doh Hea Jeong,Griffiths Elwyn,Jeong Jayoung,Jung Jaeho,Jung Yujin,Kim Byoungguk,Kim Daecheol,Meyer Heidi,Munkombwe Zuma,Oh Ilung,Ramanan Sundar,Rodgers Jacqueline,Schiestl Martin,Schreitmueller Thomas,Seng Tzer Jing,Seo Kwang-Seok,Seo Kyung Won,Shin Jinho,Sohn Yeowon,Song Suwon,Spitzer Eduardo,Suh Soo Kyung,Volkova Rauza,Wei Wei,Xie Songmei,Yamaguchi Teruhide
Funder
Ministry Food and Drug Safety (MFDS), Republic of Korea
Subject
Pharmacology,General Immunology and Microbiology,Applied Microbiology and Biotechnology,General Medicine,Bioengineering,Biotechnology
Reference10 articles.
1. Guidelines on the quality, safety, and efficacy of biotherapeutic protein products prepared by recombinant DNA technology,2014
2. Guidelines on evaluation of similar biotherapeutic products (SBPs),2013
3. Access to biotherapeutic products including similar biotherapeutic products and ensuring their quality, safety and efficacy;Resolution WHA67.21,2014
4. Regulatory system strengthening for medical products;Resolution WHA67.20,2014
5. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs),2017